BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology. 1999;117:1278-1287. [PMID: 10579968 DOI: 10.1016/s0016-5085(99)70277-5] [Cited by in Crossref: 210] [Cited by in F6Publishing: 30] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2012;11:947-957. [PMID: 22954378 DOI: 10.1517/14740338.2012.720970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
2 Banić M, Anić B, Brkić T, Ljubicić N, Plesko S, Dohoczky C, Erceg D, Petrovecki M, Stipancić I, Rotkvić I. Effect of cyclosporine in a murine model of experimental colitis. Dig Dis Sci. 2002;47:1362-1368. [PMID: 12064814 DOI: 10.1023/A:1015339018181] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J 2001;77:436-40. [PMID: 11423591 DOI: 10.1136/pmj.77.909.436] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
4 van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002;50 Suppl 3:III47-53. [PMID: 11953333 DOI: 10.1136/gut.50.suppl_3.iii47] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
5 Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
6 Lopez-Millan B, Diaz de la Guardia R, Roca-Ho H, García-Herrero CM, Lavoie JR, Rosu-Myles M, Gonzalez-Rey E, O'Valle F, Criado G, Delgado M, Menendez P. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med 2017;49:e290. [PMID: 28154372 DOI: 10.1038/emm.2016.143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
7 Bauditz J. Effective treatment of gastrointestinal bleeding with thalidomide - Chances and limitations. World J Gastroenterol 2016; 22(11): 3158-3164 [PMID: 27003992 DOI: 10.3748/wjg.v22.i11.3158] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
8 Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J. 2004;80:206-213. [PMID: 15082841 DOI: 10.1136/pgmj.2003.013722] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
9 Wang L, Hong Y, Wu J, Leung YK, Huang Y. Efficacy of thalidomide therapy in pediatric Crohn’s disease with evidence of tuberculosis. World J Gastroenterol 2017; 23(43): 7727-7734 [PMID: 29209113 DOI: 10.3748/wjg.v23.i43.7727] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;CD007351. [PMID: 19370685 DOI: 10.1002/14651858.cd007351.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
11 Baert FJ, Rutgeerts PJ. Medical therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2000;2:446-450. [PMID: 11079045 DOI: 10.1007/s11894-000-0006-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
12 Lienenlüke B, Stojanovic T, Fiebig T, Fayyazi A, Germann T, Hecker M. Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction. Br J Pharmacol. 2001;133:1414-1423. [PMID: 11498529 DOI: 10.1038/sj.bjp.0704193] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004;53:609-12. [PMID: 15016759 DOI: 10.1136/gut.2003.029710] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 3.8] [Reference Citation Analysis]
14 Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-961. [PMID: 14997189 DOI: 10.1038/sj.bjc.6601579] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 6.3] [Reference Citation Analysis]
15 Pravda J. Crohn’s disease: Evidence for involvement of unregulated transcytosis in disease etio-pathogenesis. World J Gastroenterol 2011; 17(11): 1416-1426 [PMID: 21472099 DOI: 10.3748/wjg.v17.i11.1416] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Prehn JL, Landers C, Muller GW, Man HW, Stirling DI, Targan SR. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol 2001;21:357-64. [PMID: 11720008 DOI: 10.1023/a:1012292703871] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Konrad A, Mähler M, Arni S, Flogerzi B, Klingelhöfer S, Seibold F. Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis 2005;20:9-17. [PMID: 15338166 DOI: 10.1007/s00384-004-0619-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
18 Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol 2011;2:291-308. [PMID: 23556097 DOI: 10.1177/2040620711413165] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
19 Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) 2016;95:e4239. [PMID: 27472695 DOI: 10.1097/MD.0000000000004239] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
20 He Y, Mao R, Chen F, Xu PP, Chen BL, Wu Y, Qiu Y, Zhang SH, Feng R, Zeng ZR, Ben-Horin S, Chen MH. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol 2017;10:397-406. [PMID: 28507598 DOI: 10.1177/1756283X17698910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
21 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1441-1444 [DOI: 10.11569/wcjd.v12.i6.1441] [Reference Citation Analysis]
22 Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut. 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 4.5] [Reference Citation Analysis]
23 D'Haens G, Daperno M. Advances in medical therapy for Crohn's disease. Curr Gastroenterol Rep 2002;4:506-12. [PMID: 12441041 DOI: 10.1007/s11894-002-0027-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2007;1:89-100. [PMID: 19072438 DOI: 10.1586/17474124.1.1.89] [Reference Citation Analysis]
25 Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94. [PMID: 11781268 DOI: 10.1128/cmr.15.1.79-94.2002] [Cited by in Crossref: 302] [Cited by in F6Publishing: 121] [Article Influence: 15.1] [Reference Citation Analysis]
26 Judge TA, Lichtenstein GR. Refractory Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2001;4:267-73. [PMID: 11469984 DOI: 10.1007/s11938-001-0039-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
27 Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003;79:127-32. [PMID: 12697909 DOI: 10.1136/pmj.79.929.127] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
28 Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, Silva F, Pereira Jứnior FA, Pereira MG, Tortori C, Dines I, Carvalho J, Rocha E, Elia C. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production. World J Gastroenterol 2007; 13(15): 2166-2173 [PMID: 17465495 DOI: 10.3748/wjg.v13.i15.2166] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
29 Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs. 2001;61:777-787. [PMID: 11398909 DOI: 10.2165/00003495-200161060-00006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
30 Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302. [PMID: 17037946 DOI: 10.2165/00148581-200608050-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
31 Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007;10:195-207. [PMID: 17547858 DOI: 10.1007/s11938-007-0013-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
32 Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429-448. [PMID: 11085348 DOI: 10.2165/00002018-200023050-00006] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 6.3] [Reference Citation Analysis]
33 Song G, Zhang FF, Cheng HD. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation. Australas J Dermatol 2022. [PMID: 35229882 DOI: 10.1111/ajd.13812] [Reference Citation Analysis]
34 Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 2008;57:1509-1517. [PMID: 18596194 DOI: 10.1136/gut.2008.152496] [Cited by in Crossref: 114] [Cited by in F6Publishing: 110] [Article Influence: 8.1] [Reference Citation Analysis]